Cymbopogon martini

Cymbopogon martini (Palmarosa): A Comprehensive Reference

1. Identity and Botanical Classification

Nomenclature and Taxonomy

Cymbopogon martini (Roxb.) W. Watson (family Poaceae), popularly known as palmarosa, Indian geranium, ginger-grass, and rosha-grass, is rich in volatile secondary metabolites having broad industrial relevance. The accepted botanical authority name is Cymbopogon martini (Roxb.) Will. Watson; older literature occasionally lists the spelling variant Cymbopogon martinii. The genus Cymbopogon (Poaceae) comprises up to 144 species distributed in Asia, America, and Africa, among which Cymbopogon winterianus Jowitt ex Bor, Cymbopogon citratus Stapf, and Cymbopogon martini (Roxb.) Watson are economically important species of the genus.

Morphological Description

Cymbopogon martinii is a perennial, tufted grass native to the Indian subcontinent and Indo-China, characterized by erect culms reaching 1.5–3 m in height, linear-lanceolate leaves up to 50 cm long, and aromatic foliage with a rose-like scent. It is a tall perennial grass that grows in warm humid areas; this crop is hardy and tolerates drought conditions, making it popular to grow in marginal wastelands including saline, sodic, and alkaline soils.

Varieties

Two varieties, namely motia and sofia, have been documented for C. martini. The two varieties are morphologically almost indistinguishable but show distinct characteristics based on ploidy level, essential oil profile, and odor. Molecular distinctions between motia and sofia varieties have been documented. Commercial palmarosa oil, rich in geraniol, is distilled from the motia variety, while the essential oil produced from the sofia variety, rich in p-menthadienols, is known as ginger-grass oil. In terms of morphology, C. martini var. motia grows to a height of 1.80–2.40 m and features yellow stems with dark green leaves, whereas C. martini var. sofia has a purple stem that is shorter, reaching 90–120 cm.

Geographic Distribution and Cultivation

The majority of subtropical India is home to the palmarosa plant, and India is the main exporter and producer of palmarosa essential oil. Originally from India and Vietnam, it is now cultivated in Africa (especially in Madagascar) and Australia. Countries such as India, Brazil, and Madagascar have the practice of producing essential oils from this plant. The genus Cymbopogon (Family: Poaceae) includes about 140 species, with most reported from Africa (52 species), followed by India (45 species), with others distributed across Australia, South America, Europe, North America, and the rest of South Asia.

Common Forms and Preparations

The primary commercial form of C. martini is its steam-distilled essential oil. The extraction process is steam distillation; the plant belongs to the family Poaceae, and the aerial parts of the plant are used. The resulting essential oil is a mobile, clear liquid; pale yellow to yellow in color; with a sweet, dewy, herbaceous, and floral scent. Its physical properties include a density of 0.880–0.884 g/cm³, insolubility in water, and a refractive index of 1.471–1.478. Beyond the neat essential oil, palmarosa essential oil is being developed as an alternative to synthetic fungicides; its low long-term stability and volatility prompted researchers to develop nanostructured lipid carriers (NLCs) containing the essential oil to improve stability and prolong its biological activity.

2. Traditional and Historical Use

South Asian (Ayurvedic and Folk) Traditions

Cymbopogon martinii, known in ancient Ayurvedic texts as Rohisha grass, has been recognized since antiquity for its medicinal and aromatic properties, with references appearing in classical works including the Charaka Samhita. These texts, dating from ancient times with the Charaka Samhita compiled around the 2nd century BCE to the 2nd century CE, highlight its use in traditional formulations, underscoring its long-standing presence in South Asian herbal traditions.

Palmarosa has been used in aromatherapy as a skin tonic due to its antimicrobial properties, and in Ayurvedic medicine for skin problems and to relieve nerve pain. Cymbopogon martinii (Roxb.) Watson (Family: Graminae), commonly known as Palmarosa, is traditionally prescribed for central nervous system (CNS) disorders such as neuralgia, epileptic fits, and anorexia.

Traditional Ayurvedic practitioners employed the plant in multiple preparation forms. A decoction of Rohisha was administered in a dose of 50–60 ml to manage intestinal worms and diarrhoea; the paste of leaf and stem was applied externally on areas affected by scabies and skin discolouration; the oil extract mixed with hot water was used for steam inhalation in asthma and the common cold; the plant was boiled in cow milk and given as a drink (40–50 ml) to enhance breast milk in nursing women; and a decoction (50–60 ml) was used as a blood purifier and to strengthen cardiac muscles.

The herb C. martini is traditionally used in south Asian communities for treating various ailments, including gastrointestinal, respiratory, and vascular disorders.

Industrial and Cosmetic Historical Uses

In Southeast Asia, Indian palmarosa oil has long been widely used in many commercial cosmetics and toiletry products. The palmarosa plant, also known as rosagrass, has been a significant source of essential oils utilized globally in the fragrance, cosmetic, and soap industries. The essential oil from C. martini var. motia imparts a long-lasting rose-like odor that has historically made it valuable to the soap industry.

3. Key Constituents and Active Compounds

Primary Chemical Composition of Palmarosa Oil (var. motia)

Palmarosa essential oil distinctly stands out from other Cymbopogon species oils with an exceptional concentration of monoterpenols, reaching 80 to 95% of its total composition. In palmarosa oil, geraniol is the main component, representing 82.83% of the volatile fraction. Other compounds include geranyl acetate (7.21%), linalool (7.71%), and beta-caryophyllene (1.89%), a composition that aligns with those reported in previous publications.

A broader set of constituents identified by GC-MS analysis across published studies includes: chemical profiling of the essential oils revealed eleven compounds: myrcene, cis-β-ocimene, trans-β-ocimene, linalool, neral, geraniol, geranial, geranyl acetate, caryophyllene, geranyl isobutyrate, and farnesol.

The key constituents with their reported ranges are:

• Geraniol — typically 74.5–81.0% of the essential oil; the dominant monoterpene alcohol responsible for the characteristic rose-like fragrance and the primary bioactive component.
• Geranyl acetate — 0.5–10.7%, an ester derivative of geraniol contributing to the oil's floral profile.
• Linalool — 2.6–4.5%, a minor monoterpene alcohol present across all published analyses.
• Farnesol — 0.5–6.1%, a sesquiterpene alcohol that contributes to the oil's stability and antimicrobial profile.
• Beta-caryophyllene — a minor sesquiterpene present in small quantities in most samples.

Chemical Composition of Ginger-Grass Oil (var. sofia)

The oil from C. martini var. sofia is primarily characterized by oxygenated monoterpenes (84.89%), mainly represented by (E)-p-mentha-2,8-dien-1-ol (21.0%), (E)-p-mentha-1(7),8-dien-2-ol (18.1%), (Z)-p-mentha-1(7),8-dien-2-ol (17.4%), (Z)-p-mentha-2,8-dien-1-ol (9.0%), and (E)-carveol (5.7%) — a markedly different profile from the geraniol-dominant var. motia.

Root versus Leaf Composition

Palmarosa leaves' essential oil contains neral (36.1%) and geranial (53.1%) as the major compounds, while in the roots of palmarosa essential oil, the prime components are α-elemol (31.5%), geranial (25.0%), and neral (16.6%). This indicates a substantially different chemotype depending on the plant part extracted.

Harvest-Dependent Compositional Variation

The content and composition of essential oils is known to depend on extrinsic and intrinsic factors, including climate and season of harvest, making knowledge of the optimal harvesting time necessary for production of quality essential oil.

4. Established Mechanisms of Action

Antimicrobial Mechanisms

The essential oil extracted from palmarosa (Cymbopogon martinii) has proven antimicrobial properties against cells of Saccharomyces cerevisiae; low concentrations of the oil (0.1%) inhibited the growth of S. cerevisiae cells completely. The composition was determined as 65% geraniol and 20% geranyl acetate, and the effect of palmarosa oil in causing K⁺ leakage from yeast cells was attributed mainly to geraniol. Palmarosa oil led to changes in the composition of the yeast cell membrane, with more saturated and fewer unsaturated fatty acids in the membrane after exposure.

Geraniol has demonstrated notable antimicrobial activity against several bacterial species, including Escherichia coli, Helicobacter pylori, Haemophilus influenzae, and Streptococcus pneumoniae; in addition to its antibacterial effects, geraniol shows broad antifungal activity, further supporting its potential as a multifunctional antimicrobial compound.

Beyond its antimicrobial potential, geraniol has been reported to modulate key inflammatory and antioxidant signaling pathways, and it further displays significant antinociceptive activity.

Anti-Quorum Sensing Mechanism

Geraniol (81.25%) was recorded as the main component of palmarosa essential oil and was found effective against Gram-positive and Gram-negative bacteria. The essential oil was found to reduce pyocyanin production (by 71%), elastase activity (by 64%), swarming motility (by 69%), and biofilm formation (by 64%). Furthermore, geraniol was docked against the binding region of the LasR protein and found to bind excellently with the receptor. This quorum-sensing inhibitory activity is a distinct and potentially clinically relevant mechanism, as it could attenuate bacterial virulence independently of bactericidal action.

Immunomodulatory / Anti-Inflammatory Mechanism

The immunomodulatory action of C. martinii essential oil (EO) and geraniol was evaluated regarding the production of pro- and anti-inflammatory cytokines (tumour necrosis factor (TNF)-α and IL-10, respectively) by human monocytes in vitro. TNF-α production was not affected by C. martinii and geraniol at most concentrations; on the other hand, all concentrations of C. martinii and geraniol increased IL-10 production by human monocytes. Data showed that noncytotoxic concentrations of EO and geraniol exerted an anti-inflammatory action by increasing IL-10 production; moreover, geraniol seemed to be probably responsible for EO immunomodulatory activity under these assay conditions.

Antioxidant Mechanism

In vitro study of the antioxidant activity of palmarosa essential oil employed DPPH assay, nitrogen oxide assay, reducing power assay, β-carotene bleaching assay, and FRAP method; IC₅₀ values observed for DPPH and NO assay were 0.125 mg/ml and 12.5 μg/ml, respectively. The results indicate that palmarosa essential oil is effective in scavenging free radicals and has the potential to be a powerful antioxidant.

In a rodent inhalation study, catalase and superoxide dismutase activities were higher in animals that inhaled C. martinii essential oil. These results suggest that the beneficial actions of C. martinii EO on oxidative stress can prevent toxicity in the liver, proving the possible interactions between geraniol and numerous other chemical compounds present in C. martinii EO.

In Vivo Anti-Inflammatory (Animal Model)

In vivo oral administration of essential oil extracted from Cymbopogon martini showed dose-dependent inflammation-inhibiting potential against carrageenan-induced paw edema animal model, when compared with the standard drug diclofenac sodium. This finding is from an animal model only and does not directly translate to clinical evidence in humans.

Geraniol, the major constituent of C. martinii EO, is an acyclic monoterpenoid that is abundant in many plants; it may represent a new class of therapeutic agents against pancreatic and colon cancers and has several biological properties, including antimicrobial, antioxidant, and anti-inflammatory activities. These anticancer findings are currently preclinical only.

5. Scientific Evidence by Area of Use

5.1 Antimicrobial Activity: Bacteria

Evidence type: In vitro laboratory studies; limited to no human clinical trials.

A 2025 in vitro study published in Pharmaceutics (Cebollada et al., Universidad San Jorge, Spain) investigated C. martini essential oil against human clinical bacterial isolates. The aim was to explore the antimicrobial impact of Cymbopogon martini essential oil against human clinical bacterial isolates from the skin and respiratory tract; geraniol, its main component according to GC-MS analysis, was evaluated under the same conditions; and the MIC and minimum bactericidal concentration (MBC) were determined. The essential oil showed activity against Gram-positive bacteria from the Streptococcus and Staphylococcus genera, with MIC values ranging from 125 to 250 µg mL⁻¹ for Streptococcus agalactiae, Streptococcus anginosus, Streptococcus dysgalactiae, and Streptococcus pyogenes. For most of the clinical bacteria tested, the essential oil showed lower MIC values and therefore higher antibacterial potency than isolated geraniol, indicating that other compounds found in the essential oil such as geranyl acetate may contribute to the overall effect.

When essential oils of multiple plants were tested for antibacterial activity against 22 bacteria by disc diffusion method, palmarosa oil inhibited 21 of the 22 bacterial strains tested, placing it among the most broadly active oils assessed.

A study on quorum-sensing inhibition found that palmarosa essential oil significantly inhibited Pseudomonas aeruginosa PAO1 growth, reduced pyocyanin production, elastase activity, swarming motility, and biofilm formation, while geraniol was found to successfully bind with the LasR protein in molecular docking.

Geraniol has also exhibited antimicrobial activity against several pathogens, including the fungi Malassezia furfur and Candida albicans, bacteria such as Staphylococcus epidermidis, and mites such as Rhipicephalus linnaei.

Overall evidence strength for antibacterial activity: Substantial in vitro data across multiple independent laboratories. No published randomized controlled trials (RCTs) in human subjects exist for infectious disease endpoints; all evidence remains preclinical.

5.2 Antifungal Activity

Evidence type: In vitro and animal studies; no human clinical trials identified.

Both C. martini essential oil and its combination with Chenopodium ambrosioides oil displayed strong antifungal effects; the results provide scientific validation for the use of these EOs in the treatment of dermatophyte infections. In guinea pig models both in vitro and in vivo, Cymbopogon martini and Chenopodium ambrosioides were effective against fungal dermatophyte infections.

Cymbopogon martinii (palmarosa) was identified as one of the most antifungal of eight tested essential oils against eight tested strains in a comparative screening study.

Palmarosa essential oil is described as an alternative to synthetic fungicides to control contamination by food-deteriorating fungi, such as Aspergillus nomius. Nanostructured lipid carrier (NLC) formulations of palmarosa essential oil were developed to address its volatility and stability limitations: the nanocarriers presented particle sizes smaller than 300 nm, homogeneous size distribution, and zeta potential of −25.19 to −41.81 mV, with formulations achieving mycelial growth inhibition values up to 98.75%.

All twelve fungi tested in one comparative study were inhibited by palmarosa oil, alongside oils from aegle, citronella, geranium, lemongrass, orange, and patchouli.

Overall evidence strength for antifungal activity: Consistent and reproducible in vitro data, with supporting in vivo animal data for dermatophytes. No human RCTs; evidence is preclinical.

5.3 Immunomodulatory and Anti-Inflammatory Effects

Evidence type: In vitro (human monocyte) study; animal model study; no human clinical trials.

The most directly informative study used human immune cells. In this study, IL-10 production by human monocytes was measured when incubated with C. martinii essential oil at concentrations of 0.1, 1, 5, and 10 μg/ml, and geraniol at 0.057, 0.57, 2.87, and 5.74 μg/ml, with data representing the median of 10 similar experiments. Phytochemical analysis of the EO indicated the presence of geraniol (65–85%) and geranyl acetate (5–20%) as major components, with noncytotoxic effects determined by MTT assay.

Overall evidence strength: One in vitro study on human monocytes supports an anti-inflammatory mechanism via IL-10 upregulation. This is consistent with in vivo animal data (carrageenan paw edema model). No controlled clinical evidence in humans.

5.4 Antioxidant Activity

Evidence type: In vitro biochemical assays; animal inhalation study.

A study has shown that the essential oil of C. martini, when in vitro tested for antioxidant activity, showed a positive response and was found effective in scavenging free radicals. Antioxidant enzyme activity was also observed in a rodent model: the effects of inhalation of Cymbopogon martinii essential oil and geraniol on Wistar rats were evaluated for biochemical parameters and hepatic oxidative stress; rats were divided into three groups (n=8) — a control group treated with saline, a group receiving geraniol, and a group receiving C. martinii EO by inhalation for 30 days. No significant differences were observed in glycemia and triacylglycerol levels, and both geraniol and EO decreased (P < 0.05) total cholesterol levels. There were no differences in serum protein, urea, aspartate aminotransferase activity, and total hepatic protein.

Overall evidence strength: In vitro antioxidant data is consistent across multiple assay methods. Rodent inhalation data provides additional mechanistic support. No human trials.

5.5 Skin Health and Dermatological Applications

Evidence type: In vitro studies against skin-relevant pathogens; inflammation model; no published human clinical RCTs specific to C. martini.

The effect of palmarosa oil against Cutibacterium acnes bacteria on shoulder skin was assessed (Murbach Teles Andrade et al., 2018, Journal of Pharmacy and Pharmacology, 70(12), 1688–1699); palmarosa essential oil showed antibacterial activity against the bacteria that can cause skin acne with geraniol as the most likely active constituent, though more research is warranted.

The essential oil's activity against skin-relevant pathogens was specifically investigated in the 2025 Cebollada et al. study: the aim included exploring the antimicrobial impact of C. martini essential oil against human clinical bacterial isolates from the skin and respiratory tract. The skin inflammation model for var. sofia also showed relevant activity: Cymbopogon martini variety sofia, commonly known as ginger-grass, is an important aromatic crop used by the perfumery, medicinal, and cosmetic industries worldwide; a study explored the chemical and possible pharmacological profile of hydrodistilled essential oil of C. martini variety sofia against skin inflammation.

Overall evidence strength: Predominantly in vitro, with relevant activity against acne-associated and skin-infecting bacteria. No published human clinical trials. Traditional topical use is well-documented.

5.6 Central Nervous System: Neuralgia and Neurological Conditions (Traditional)

Evidence type: Traditional documentation; animal study only.

Cymbopogon martinii (Roxb.) Watson, popularly known as palmarosa, exhibits beneficial effects on several central nervous system pathologies, mainly neuralgia, epileptic fits, and anorexia. There are few reports on its effects; still, C. martinii has attracted researchers' attention due to its antimicrobial, antigenotoxic, and antioxidant activities. One PubMed-indexed reference cited in the rodent inhalation study includes research on neuroprotective activity of Cymbopogon martinii against cerebral ischemia/reperfusion-induced oxidative stress in rats, though the details of that study were not independently retrievable in peer-reviewed sources during the preparation of this article.

Overall evidence strength for CNS applications: Limited to traditional use documentation and animal model data. No human clinical evidence identified.

5.7 Food Safety and Preservation

Evidence type: In vitro laboratory studies.

Palmarosa (Cymbopogon martinii) is a perennial and aromatic plant whose leaves and flowers produce an essential oil considered safe by the Food and Drug Administration (FDA); palmarosa essential oil is recognized for its antifungal, antibacterial, and antioxidant properties.

The antifungal and antitumor activity of a palmarosa essential oil/β-cyclodextrin (β-CD) complex was evaluated, showing reduced mycelial growth against Aspergillus flavus and Fusarium verticillioides strains compared to the free essential oil. The development of β-CD encapsulation and NLC formulations reflects active interest in applying palmarosa's antifungal activity in food preservation settings.

5.8 Anticancer and Chemopreventive Activity (Preclinical Only)

Evidence type: Preclinical in vitro and in vivo animal studies for geraniol; no human trials.

Geraniol represents a promising dietary chemopreventive agent; its chemopreventive effect was evaluated in colon tumor induced by dimethylhydrazine in vivo in male Wistar rats, where the number of total aberrant crypt foci in the distal colon significantly decreased and apoptosis level in the distal colon was significantly higher. In combination with 5-FU, geraniol increased the apoptosis of the Caco-2 cell line in vitro.

Interesting activity against tumor cells (HeLa and HT-29) was observed against tested β-cyclodextrin/palmarosa essential oil complexes, emphasizing the potential of β-CD for the stability of natural compounds.

Overall evidence strength: Preclinical only; all anticancer findings are from cell lines or animal models. Extrapolation to human cancer prevention or treatment is not supported by clinical evidence.

6. Body Systems and Health Areas of Association

• Integumentary system (skin): The plant is an important medicinal plant known for its rich essential oil content, which has exerted antifungal, antibacterial, antiviral, anthelmintic, antioxidant, and cytotoxic activity relevant to skin health; activity against acne-causing bacteria and dermatophytes (ringworm-causing fungi) has been reported across multiple studies.
• Immune / inflammatory system: Modulation of IL-10 and TNF-α production in human monocytes (in vitro).
• Hepatic / antioxidant system: Upregulation of catalase and superoxide dismutase in rodent inhalation studies.
• Gastrointestinal system: Traditional use for intestinal worms, diarrhoea, and gastrointestinal discomfort; in vitro antifungal activity against food-borne fungi.
• Respiratory system: Traditional steam inhalation use for asthma and the common cold; in vitro antibacterial activity against respiratory tract pathogens demonstrated in clinical isolate testing.
• Nervous system: Traditional documentation for neuralgia, epileptic fits, and anorexia; animal neuroprotection data cited in the literature.
• Cardiovascular system: Traditional use as a cardiac tonic; in vivo and rodent study data showing cholesterol-lowering effect of EO inhalation; no human clinical cardiovascular data.
• Reproductive / lactation (traditional only): Traditional use of plant decoctions in cow milk reported for supporting lactation in nursing women.

7. Dosage Forms and Dosages Reported in Studies

All dosage data below is taken directly from published research; no clinical dosing recommendations have been established through human trials for C. martini.

• In vitro antimicrobial testing (Cebollada et al., 2025): MIC values for the essential oil against Streptococcus species ranged from 125 to 250 µg mL⁻¹.
• In vitro antimicrobial testing (Prashara et al., 2003, Phytochemistry): Low concentrations of palmarosa oil at 0.1% inhibited the growth of S. cerevisiae cells completely.
• In vitro immunomodulatory study (human monocytes): C. martinii essential oil was tested at concentrations of 0.1, 1, 5, and 10 μg/ml, and geraniol at 0.057, 0.57, 2.87, and 5.74 μg/ml.
• Rodent inhalation study (Andrade et al., 2014): Wistar rats (n=8 per group) inhaled C. martinii essential oil or isolated geraniol for a period of 30 days.
• Quorum sensing inhibition study: The essential oil reduced pyocyanin production (by 71%), elastase activity (by 64%), swarming motility (by 69%), and biofilm formation (by 64%).
• Traditional Ayurvedic dosage (decoctions): A decoction of Rohisha was administered in a dose of 50–60 ml to manage intestinal worms and diarrhoea. This is a traditional preparation dose, not a clinically validated therapeutic dose.
• Topical application in perfumery (IFRA guidance for geraniol): IFRA restricts palmarosa based on its geraniol content (dermal sensitization risk); maximum permitted levels vary by product category, with leave-on products limited to approximately 0.3–5.3% geraniol in the finished product depending on application type.
• Topical application reference (aromatherapy literature): Based on a maximum of 81% geraniol content, the second edition of Essential Oil Safety by Robert Tisserand recommends a maximum adult topical application level of 6.5% for palmarosa oil.

8. Safety Considerations and Known Interactions

Regulatory Status

Palmarosa (Cymbopogon martinii) essential oil is considered safe by the Food and Drug Administration (FDA). EWG Skin Deep ratings for Cymbopogon martini essential oil cite low cancer concern, high allergies and immunotoxicity concern, and low developmental and reproductive toxicity concern, citing data sources including the FDA, Environment Canada, EU Cosmetics Directive, European Chemicals Agency (ECHA), and the International Fragrance Association (IFRA).

Dermal Sensitization

Geraniol, the principal constituent, is a recognized contact allergen and is regulated by IFRA. Data from sensitization testing provided geraniol a No Expected Sensitization Induction Level (NESIL) of 11,000 μg/cm² for the skin sensitization endpoint; geraniol is not expected to be phototoxic or photoallergenic. Nonetheless, IFRA restricts its use-concentration in finished products due to sensitization potential at higher levels: IFRA limits for leave-on products are approximately 0.3–5.3% geraniol in the finished product depending on application type.

Hepatic Safety Considerations (Animal Study)

An important finding from the 30-day rodent inhalation study is that isolated geraniol and the whole essential oil produced different hepatic safety profiles. The oxidative stress caused by geraniol alone appeared to trigger, to some degree, hepatic toxicity as verified by increases in serum creatinine and ALT; the beneficial actions of C. martinii EO on oxidative stress appeared to prevent this toxicity in the liver, proving the possible interactions between geraniol and the numerous other chemical compounds present in C. martinii EO. This finding suggests that isolated geraniol may carry different safety implications than the whole essential oil, though the relevance to typical human exposure levels is unclear.

CYP Enzyme Interactions (Theoretical)

Because of the effects of citral and geraniol in inhibiting CYP2B6 enzymes, there is a theoretical risk with palmarosa for those that take drugs metabolized via this pathway if using this oil orally. This is a theoretical interaction derived from in vitro enzymatic data; it has not been evaluated in human pharmacokinetic studies.

Adulteration Concerns

Palmarosa is often adulterated with its close relative the ginger-grass plant. Turpentine and citronella oil are often used with synthetic geraniol to adulterate palmarosa. Authentication by GC-MS analysis, including chiral separation, is recommended: enantiomeric distributions of chiral terpenoids present in Cymbopogon species essential oils have been successfully used for species identification and adulteration detection.

Evidence Gaps and Limitations

Due to its outstanding antioxidant potential, C. martinii has been used as part of conventional medicine and beauty products; however, regardless of its importance, complete pharmacological and phytochemical studies are still in their early stages. The current scientific literature on Cymbopogon martini is dominated by in vitro and preclinical animal studies; no large-scale randomized controlled trials in human subjects have been published for any indication. Mechanistic data for geraniol and the whole essential oil are generally consistent, but clinical translation remains unestablished. All health-relevant findings for this ingredient should be interpreted accordingly.

References

• Cebollada P, Alvarado E, Seral C, López V. Antibacterial Activity of Palmarosa (Cymbopogon martini) Essential Oil and Geraniol Against Clinical Isolates from Respiratory, Skin, and Soft Tissue Infections. Pharmaceutics. 2025;18(1):39. PMC.
• Andrade BFMT et al. Cymbopogon martinii essential oil and geraniol at noncytotoxic concentrations exerted immunomodulatory/anti-inflammatory effects in human monocytes. J Pharm Pharmacol. 2014;66(10):1491–1496. PubMed.
• Prashara A, Hili P, Veness RG, Evans CS. Antimicrobial action of palmarosa oil (Cymbopogon martinii) on Saccharomyces cerevisiae. Phytochemistry. 2003;63(5):569–575. PubMed.
• Prasad CS, Shukla R, Kumar A, Dubey NK. In vitro and in vivo antifungal activity of essential oils of Cymbopogon martini and Chenopodium ambrosioides and their synergism against dermatophytes. Mycoses. 2010;53(2):123–129. PubMed.
• Andrade BFMT et al. Effect of Inhaling Cymbopogon martinii Essential Oil and Geraniol on Serum Biochemistry Parameters and Oxidative Stress in Rats. Biochemistry Research International. 2014;2014:493183. PMC.
• Design of Nanostructured Lipid Carriers Containing Cymbopogon martinii (Palmarosa) Essential Oil against Aspergillus nomius. PMC.
• Essential Oil Composition Analysis of Cymbopogon Species from Eastern Nepal by GC-MS and Chiral GC-MS, and Antimicrobial Activity of Some Major Compounds. PMC.
• Pharmaceutical, cosmeceutical, food additive and agricultural perspectives of Cymbopogon martini: A potential industrial aromatic crop. South African Journal of Botany. ScienceDirect.
• Changes in the essential oil content and composition of palmarosa (Cymbopogon martini) harvested at different stages and short intervals in two different seasons. Industrial Crops and Products. ScienceDirect.
• New green solutions against bacterial resistance: palmarosa (Cymbopogon martini) essential oil and quorum sensing. ScienceDirect.
• Geraniol — an overview. ScienceDirect Topics.
• Cymbopogon martinii — an overview. ScienceDirect Topics.
• The aromatic crop rosagrass (Cymbopogon martinii var. motia) — high yielding genotypes, perfumery, and pharmacological potential: A review. ScienceDirect.
• Underutilized Plant Cymbopogon martinii Derived Essential Oil Is Excellent Source of Bioactives with Diverse Biological Activities. PubMed.
• A review on the medicinal and aromatic Plant — Cymbopogon martinii (Roxb.) Watson (Palmarosa). ResearchGate.
• Cymbopogon martinii — Grokipedia.